As the global medical community converges on Milan for the 2026 European Association for the Study of Diabetes (EASD) congress, a stark reality has emerged regarding the management of type 2 diabetes. Despite rapid technological advancements in continuous glucose monitoring (CGM) and the pharmaceutical surge of glucagon-like peptide-1 (GLP-1) receptor agonists, a comprehensive new study from Dexcom suggests that the promise of these "miracle" tools remains out of reach for a significant portion of the patient population.
The 2026 State of Type 2 report, released by Dexcom ahead of the EASD summit, serves as both a roadmap for future clinical intervention and a cautionary tale regarding the disparities in healthcare equity and patient education.
The Landscape of the Challenge: Main Facts
The Dexcom report, which synthesized data from approximately 2,500 patients and over 800 healthcare professionals (HCPs) across eight nations—including the US, Germany, Italy, and the UK—paints a picture of a fractured care ecosystem. While clinical evidence continues to mount in favor of pairing digital monitoring with pharmacological therapy, the "last mile" of delivery is failing.
The core findings are twofold: first, there is a profound lack of patient-level awareness regarding the availability and utility of CGMs. Second, for those who are aware, systemic barriers such as insurance coverage and reimbursement policy act as formidable gatekeepers, preventing widespread adoption.
For the millions living with type 2 diabetes, these barriers are not merely bureaucratic; they are obstacles to better health outcomes, reduced hospitalization rates, and a higher quality of life. The report underscores that the efficacy of modern diabetes tools is currently capped by a lack of infrastructure, rather than a lack of science.
Chronology of the Crisis: From Innovation to Stagnation
To understand the current state of affairs, one must look at the timeline of the "diabetes revolution."
- 2020–2022: The emergence of GLP-1s as a household name began to reshape the metabolic health landscape, shifting the focus from mere glucose management to comprehensive metabolic improvement.
- 2023–2024: During this period, clinical evidence began to solidify the idea that CGM data could provide the "feedback loop" necessary to make GLP-1 therapy more effective. Awareness of these tools among patients grew, with Dexcom data indicating that awareness of GLP-1s as a complementary tool rose from 21% in 2024 to 37% by 2026.
- 2025: Throughout the last year, pilot programs in various health systems experimented with bundled care, yet the report suggests that these initiatives failed to scale effectively.
- September 2026: The release of the State of Type 2 report ahead of the EASD congress marks a pivotal moment. It serves as a formal acknowledgment that despite the rapid growth of the market, the vast majority of patients are being left behind by an information and access gap that has failed to close in the last 24 months.
Supporting Data: The Metrics of Disparity
The data provided by Dexcom is granular, exposing the disconnect between what doctors know and what patients experience.
The Awareness Gap
Perhaps the most startling statistic from the report is that 55% of respondents with type 2 diabetes reported having little to no knowledge of CGM as a viable option for their condition. This suggests that even as these devices become standard of care for type 1 diabetes, they are still viewed as "niche" or "unnecessary" for those with type 2, despite the massive clinical benefit.
The Financial Barrier
The barriers to entry vary by geography, yet the theme of financial obstruction remains constant. In the United States, 90% of surveyed HCPs identified coverage limitations—such as insurance denials, high co-pays, or narrow eligibility criteria—as the primary obstacle to prescribing CGMs. In the seven other countries surveyed, 53% of clinicians pointed to reimbursement policies as the main hurdle.
The Synergy Gap
Perhaps the most significant clinical opportunity missed is the "synergy" between CGM and GLP-1s. While clinical studies have repeatedly shown that patients who track their glucose while on GLP-1 medication experience better adherence and metabolic control, the adoption rate remains low.
- Only 27% of non-insulin-using type 2 patients utilize a CGM alongside their medication.
- 72% of all type 2 patients remain unaware that the two tools are designed to work in tandem.
Clinical Implications: The Transformation of Care
Despite these hurdles, the report offers a compelling argument for why change is necessary. For the minority of patients who have successfully integrated CGMs into their routine, the results are transformative.
The survey revealed that 94% of CGM users report managing their condition with greater independence. This autonomy is not trivial; it represents a shift from reactive care—waiting for the next doctor’s appointment—to proactive, data-driven self-management. 91% of these users actively utilize their glucose data to inform their daily treatment decisions, such as dietary adjustments and exercise timing.
For HCPs, the benefits are equally clear. 89% of doctors surveyed stated that CGM usage provides a vital window into treatment adherence between clinic visits. Instead of relying on periodic A1c tests—which provide a three-month average but miss daily fluctuations—doctors can now view a high-resolution map of a patient’s glycemic health. This allows for more precise adjustments to medication, which in turn leads to higher patient morale and better clinical outcomes.
Official Responses and Strategic Outlook
Jake Leach, President and CEO of Dexcom, framed the findings as a rallying cry for the industry.
"The 2026 Dexcom State of Type 2 Report builds on last year’s finding that CGM is the foundation of successful type 2 diabetes management," Leach stated. "This year’s data reinforces that truth and reveals exactly where the barriers remain: not in clinical efficacy, but in awareness and access for all people with type 2 diabetes."
The implication of Leach’s statement is clear: the technology is no longer the variable that needs improvement. The focus must now shift to public health policy, insurance reform, and physician education.
The Path Forward: Education and Integration
The report suggests that the "convergence" of CGMs and GLP-1s is currently underutilized. For the healthcare industry, the next phase of development must focus on:
- Patient Literacy: Campaigns aimed at closing the 55% awareness gap, specifically targeting those who feel their type 2 diabetes is "mild" or "under control."
- HCP Education: Addressing the fact that only 43% of HCPs currently view the CGM-GLP-1 pairing as a standard complementary tool.
- Policy Advocacy: Working with national health services and private insurers to prove that the upfront cost of a CGM is a cost-saver in the long term, preventing the downstream complications of poorly managed diabetes.
Conclusion: The Milan Mandate
As researchers, clinicians, and industry leaders gather in Milan for the 2026 EASD congress, the State of Type 2 report will undoubtedly serve as a focal point for panel discussions and policy debates. The message is as urgent as it is clear: the tools to fundamentally transform the lives of millions are ready, but the systems surrounding them are not.
If the industry is to move past the current plateau of "awareness," it must prioritize equity of access. Without systemic changes to reimbursement and a renewed commitment to patient education, the disparity between those who benefit from modern diabetes tech and those who remain in the dark will only continue to widen. The goal for the coming year, therefore, is not just the development of more advanced hardware, but the construction of a more accessible, integrated, and informed healthcare landscape for all people living with type 2 diabetes.
About the Author
